{"ticker": {"uuid": "2734d6d2-877e-48c1-8212-8df270991a87", "symbol": "LSTA", "name": "Lisata Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered", "summary": "Kuva Acquisition Corp. has extended its tender offer for Lisata Therapeutics (LSTA) shares to July 16, 2026, with the offer price remaining at $4.00 cash per share plus one contingent value right (CVR) for potential additional payments up to $3.00. Over 5.1 million shares, repres", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-to-t-a-lisata-therapeutics-inc-amended-third-party-tender-offer-adef75046189.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:13", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lisata Therapeutics, Inc. \u2013 NASDAQ:LSTA", "summary": "This article provides the \"Price to sales forward\" value for Lisata Therapeutics, Inc. (NASDAQ: LSTA). It presents the company's stock information, including its ticker symbol, exchange, and market status. Although the specific financial value is not displayed, the article focuse", "url": "https://www.tradingview.com/symbols/NASDAQ-LSTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T16:41:33", "published_display": "08 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline - EPS Growth Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQNnNKbFRGM1dxSWFQMnB6SFJXdVdwejVNYXZveGNETVRpUUxMTUpxcUxZY3F1dllQajV1ZTVQNENZdVJEMHBXazNEQkhERXViVWh3RzVTYV9hcW5NdVhCZElxTlFWUE8zT0ZWcXJkcU5DYU94YTQ5VWdKa0VrVDRNV3hYSkZCRFVzX0RRNFd2Vzhya1NlOC01S2VpWGdXQUYwM3lZeGpwRU5ldnRkcjJJSmQ0QzItOWhpNWJoQ0g1Mk0wUFdoZVZZM1VjSmNlZWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:48:31+00:00", "published_display": "07 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) amends 14D-9, restates $4.00 cash offer plus CVR", "summary": "Lisata Therapeutics has amended its Schedule 14D-9 filing to provide additional disclosures regarding the proposed tender offer by Kuva Acquisition Corp. The amendment clarifies board deliberations, an alternative offer, fairness analyses, and includes details about six demand le", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-14d9-a-lisata-therapeutics-inc-amended-tender-offer-recommendation-bff20fb233f8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:27", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA - Lisata Therapeutics Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a detailed financial and news overview of Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It includes stock performance data, key financial metrics, insider and institutional ownership, and a comprehensive list of corporate news rele", "url": "https://finviz.com/stock?t=LSTA&p=d&ty=tr", "source_name": "Finviz", "published_at": "2026-07-02T10:10:27", "published_display": "02 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE)", "summary": "This article provides current financial actuals and estimates for Lisata Therapeutics, Inc. (DUS:8NE), including income statement, balance sheet, and cash flow data. It also covers stock performance details like all-time high/lows, upcoming earnings dates, net income, EBITDA, and", "url": "https://www.tradingview.com/symbols/DUS-8NE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T23:39:18", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides financial information and forecasts for Lisata Therapeutics, Inc. (LSTA), including its stock ticker, historical prices, earnings reports, net income, EBITDA, and employee count. It also addresses frequently asked questions about buying LSTA shares and confi", "url": "https://www.tradingview.com/symbols/BOATS-LSTA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:11:38", "published_display": "26 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing", "summary": "Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (LSTA) on behalf of investors who suffered losses due to disclosures regarding the financing of its proposed acquisition by Kuva Labs, Inc. The investigation follows multiple amendments and delays in the tender offer", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318335/0/en/johnson-fistel-investigates-lisata-therapeutics-inc-lsta-after-disclosures-concerning-acquisition-financing.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T15:11:38", "published_display": "26 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA)", "summary": "This article provides an overview of Lisata Therapeutics, Inc. (NASDAQ: LSTA), covering its current stock price, historical performance, market capitalization, and financial estimates. It highlights key financial data like net income and EBITDA, upcoming earnings dates, and addre", "url": "https://www.tradingview.com/symbols/NASDAQ-LSTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:38", "published_display": "26 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lisata Therapeutics Inc (LSTA), highlighting its price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. As of June 24, 2026, LSTA has a price momentum score of 7.10, wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/technical", "source_name": "TradingKey", "published_at": "2026-06-25T00:09:48", "published_display": "25 Jun 2026 00:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA: Kuva Tender Offer Uncertainty Will Ultimately Support Future Upside Potential", "summary": "Analyst price targets for Lisata Therapeutics have been reduced to $4.00, reflecting increased uncertainty surrounding the proposed Kuva Labs acquisition. Under the tender offer, Lisata shareholders are offered $4.00 cash per share plus a contingent value right (CVR) that could p", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-lsta/lisata-therapeutics/5j4aci8v-positive-clinical-trials-will-expand-precision-oncology-markets-wgss/updates/13-analysts-have-reduced-their-price-target-for-lisata-therapeu", "source_name": "Simply Wall Street", "published_at": "2026-06-23T12:10:45", "published_display": "23 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Institutional Confidence", "summary": "Lisata Therapeutics Inc (LSTA) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 34.03% quarter-over-quarter to 10.92%. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:04", "published_display": "22 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lisata Therapeutics Inc (LSTA) has an earnings forecast score of 7.33, ranking 295 out of 388 in its industry. Analysts have set an average price target of $15.00 for LSTA, with a high of $15.00 and a low of $9.00, and predominantly recommend a \"Buy\" rating for the stock. This an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:09", "published_display": "17 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Lisata Therapeutics Inc (LSTA), including its business segments, regional revenue, and profit contribution. It notes that relevant financial data for these categories have not yet been disclosed by the company. The page provides a ge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lisata Therapeutics Inc (LSTA) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and details a 15-to-1 merger-related stock split that occurred on Septembe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)", "summary": "Brodsky & Smith is investigating potential claims against Lisata Therapeutics, Inc. (LSTA) regarding its sale to Kuva Labs, Inc. for $4.00 per share cash plus two contingent value rights. The investigation focuses on whether Lisata's Board of Directors breached fiduciary duties b", "url": "https://www.newsfilecorp.com/release/301602/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Lisata-Therapeutics-Inc.-LSTA", "source_name": "TMX Newsfile", "published_at": "2026-06-15T21:09:50", "published_display": "15 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.", "summary": "Lisata Therapeutics has announced the commencement of a cash tender offer by Kuva Labs Inc., facilitated through its wholly-owned subsidiary, Kuva Merger Sub Inc. This offer is for all outstanding shares of Lisata's common stock at an acquisition price of $0.90 per share. The ten", "url": "https://www.moomoo.com/news/post/71331193/press-release-lisata-therapeutics-announces-commencement-of-tender-offer-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-11T08:39:38", "published_display": "11 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share", "summary": "Lisata Therapeutics has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right up to an additional $3.00 per share tied to drug development milestones. The tender offer launched on June 10, with the offer period set to expir", "url": "https://www.proactiveinvestors.ca/companies/news/1093720/lisata-therapeutics-agrees-to-kuva-labs-buyout-at-4-per-share-1093720.html?region=ca", "source_name": "Proactive financial news", "published_at": "2026-06-11T07:40:02", "published_display": "11 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.", "summary": "Lisata Therapeutics announced that Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., has commenced a tender offer to acquire all outstanding shares of Lisata common stock. Stockholders will receive $4.00 per share in cash plus one non-tradeable contingent value right (CVR) ", "url": "https://www.globenewswire.com/news-release/2026/06/10/3309632/0/en/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T18:09:51", "published_display": "10 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SC TO-T] LISATA THERAPEUTICS, INC. Third-Party Tender Offer | LSTA SEC Filing - Form SC TO-T", "summary": "This SEC filing (Form SC TO-T) details a third-party tender offer by Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., to purchase all outstanding common shares of Lisata Therapeutics, Inc. for $4.00 per share in cash plus one contingent value right (CVR) that could yield a", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-to-t-lisata-therapeutics-inc-third-party-tender-offer-79b13409144c.html", "source_name": "Stock Titan", "published_at": "2026-06-10T11:39:36", "published_display": "10 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SC 14D9] LISATA THERAPEUTICS, INC. Tender Offer Recommendation", "summary": "Lisata Therapeutics, Inc. (LSTA) has filed an SC 14D9 recommending shareholders accept a tender offer from Kuva Acquisition Corp., a wholly-owned subsidiary of Kuva Labs Inc. The offer comprises $4.00 per common share in cash upfront, plus one non-tradeable contingent value right", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-14d9-lisata-therapeutics-inc-tender-offer-recommendation-654536a584c9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T08:39:36", "published_display": "10 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQWk52cDdkWURDbWNJa1Y3bUFTTHNuSDc5SXRDYXBnUmJrUXBNWExlazh2Q2pOQWFfN0FMQUJWc0hmUXBoTUJkeUlEYlNXZEg3OE1qR3VzUDZlZzNtSkdnckxsTS1PQUxJLWpaS2E5U2xnRHdSdkFjdHVqaFhfMG5ta0JneW1nN3BkUW5wbzE5TlZSRWhwdGhocnhHV1VkaURvZGxmTDUwRmE0aHZVcFotMU5aelBsM0FXbWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA SEC Filings - Lisata Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides a comprehensive resource for investors to access official regulatory documents for Lisata Therapeutics (LSTA), including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Recent filings detail events such as a non-exclusive AD", "url": "https://www.stocktitan.net/sec-filings/LSTA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T04:39:37", "published_display": "10 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee", "summary": "Lisata Therapeutics and Kuva Labs have amended their merger agreement, extending the tender offer commencement deadline to June 10, 2026, and the transaction \"Outside Date\" to July 17, 2026, with an option for further extension to August 17, 2026, for a $1.5 million fee. Lisata a", "url": "https://www.stocktitan.net/sec-filings/LSTA/8-k-lisata-therapeutics-inc-reports-material-event-4f16e3c4dccb.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:17", "published_display": "09 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17", "summary": "Lisata Therapeutics has extended its merger agreement with Kuva Labs by signing an Amendment and Waiver. This adjustment moves the \"Outside Date\" to July 17, 2026, with a further option to extend to August 17, 2026, for a $1.5 million payment, aiming to navigate financing uncerta", "url": "https://www.tradingview.com/news/tradingview:7ffa76673cfb0:0-lisata-extends-kuva-labs-merger-timeline-outside-date-to-july-17-1-5-million-option-to-aug-17/", "source_name": "TradingView", "published_at": "2026-06-09T11:10:17", "published_display": "09 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA - Lisata Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It lists key financial metrics, stock performance indicators, and recent news headlines including acquisition efforts by Kuva Labs and vari", "url": "https://finviz.com/stock?t=LSTA", "source_name": "Finviz", "published_at": "2026-06-08T05:11:22", "published_display": "08 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPeTlSVVRnTTRRNG40ZW5KVDFxR2ZFRTFqWFNqSENCa0dVeFpkR2FJLVNfcTV2MzdodXRaOXI2cnhJZEdwZ21vSGExeXo2OGdmRHVVVXRSdHNwc2E1YVNaNGFfbG5Jc1lhaUxkRlZkckZGcTctYjUwcHczeDlTNEdYcmVRaFlFSzVraEQ0anAxcTJMM1daLVVMLWdUeFFMYkt0SzRXSjRobVRIREdSNUVBTldR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNVjVPaWdpOFJGQmJwMHFNSGU3aGZJenp3bmF2NUMwX1FrU1hidGxEbjVFSkI3SlBSSTU1cldNbnBuTDE3YUx4MFZEQWhfaHpsS3BLWUxEQzZiZU9uZEstdjVUTXBHcGk2VWoyRTY3YkFvX2JfUGtDUERIcXR5dVVscVlUVFZ6VTFMaEExck8weHNkb0xuYmNlX0ttNUVIUEpLMTdxd2JBVXlNUEZ0MElPMDdzM1A3Ulp1X2RucWtpdWs4b1c4MmFSc1NITDdqWEk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Slightly Lower: Assessing Support Levels and Potential Catalysts - Sign of Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbGIxX2xQMmtjRjhzLThaakNYUTI4bXpNbGtZOEdscjByZkhOWXVDRkU1Q3loVWllOGpIVTdkUkpTSkhia3pfeXozRVROaWJfdm5yMzhTY2NjVkU4WWVycWNxQkUyamkyMU55WGxXcHZWNC03N3ltWUZ4TUZnZ2FXNS1xdFh1ZE1jX2tXbVZiZmZ2QkFZNkpiV2UxT21JcDIxc09CaGpaQlU0OHZlTjNYOG0wa09zdTNPZ01XZnBmT29EczVOSkF2VU94ZnlwQUFTdlVz?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSXpTNC1GaVF1ODBMSGtEdldSZDhhcDQ3LWEwdnkzUVVENWJvR0d4NHZPVzJEUzlqYzY2WmJpNmlVcDBNb0pqUFNsdDNrSHo3UnZwTzN2Z1hMWnlOMXhoa1ZtYzRrd2pvQk0xNW9hOE1KYUtRVmtoMzZHR1ItbHNrN1hibzlNMW1rOV9jekdORXZaZnFNeW9RRENuWWxsLU9MQlEyRFpiV3VfT1RNQzlqU0RR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPUnYtOHR0cTg0ZWFqQU1HaDVqZmctY2lreXloYVZjR3oxaEpkRTRqNzdwNm5vTWxValZmT2dGNEp1dk1mR0EwaDlLT2R1MXM3aVdEaTZ1bnlqUWFHazFIT0NKSTd1VmEzeEx2Y0I3Sy1URjREMHFDc1R3VGxfdTZ3RTR0UFhKYXVIaXpON3FwSEV6anVfd20zNl84TmJ1amZES29OdUtOUWhTMlUzQjlNMnBB?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-17T03:48:52+00:00", "published_display": "17 Mar 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNSGtWMldYbl9pOXRmNkpfT3dic0tuQ2docE1pZ0Z1Q3dpckNDVVpra2tnOWM4UFpXZ094eWV4NVlLZWE2TXQyVlcyejNZeUY2bkg0Vl9maDNqeHZ5Q2ViS2ZWSVREVGJrc0ZJcV9INTdUVGFpOTFYNWhUSzBXSlI3WlFfWk5EdW5YVHVaZw?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOMF9vdVdTNUlPejRZbnlfcGF4Um5FdnV3d1lsa0dTZ0FEVnItRUk1ZHpnRmRVRXBYSkp6NlRKM2FyRFBkZFZNaUNHYzFLUlQ2cGk0MXJ2Mm1XcW9jS05EOHZES0pPX3VIM0QyOEVyTkRIdW14STN4VzBWWFZzNVptQkpWd0k4QXB2X2RmOVRuWkJ6NFB1UFNjSkk2ejkwRExoY0tNay1DQ09pUjY0S3dJTUxVakg3Nkc3UXlXTndwMGtXSVJiU1o1dmkwNHJxZndKWXFkZkZCdzBwYUt4SGt5dGIxLVE1M094akZFYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Shares Nearly Double On Buyout Offer: Here Are The Details", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNSXFETkIzWkZGRHVIdUp3MXBXR0pyVkFSa2NzMHRRdm9kN1BaOTNYZUVDVkhHYjBFS0NQSUdRSGlCRVE5cjZjcVF3VWlqY1U3VHZVS1ZGNVZBSjF4UXROZnVETDNMWmhxNW5oT25xaWVSZ2labXVWQWU2dEpGMHJjVlNSaGNXZkxhSEFRUmtwOTd1aWhxQmZZWkMzb1VhRm5ZcmNwN1I4aXB4bUk?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOam1ERFVaMS1JemRLU290VUxla1Z5VnprNTBTbWE4QnBjYWhGQ0dKU0JnZFBSWERRa3E4UlJtT2g2S25nUUNGWHZ0eEx3d0EyMTJLOXJKZXN2ZUNMcThJS0wyRVR6aGJ5TTF6OHhrU3h2LU9vcktENkJnSUF3dTdtamxKQV95QTN3VmN4OTRFY2tsRHI0c3JvN2RQWXVtR3dqc0ZfVjIxalY?oc=5", "source_name": "citybiz", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Enters Into Term Sheet to be Acquired", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxOSW0tSmtJUE1wNW5rY2JnbWFBT2NhRXdpVElKbkkwYTEtZlRrbFdtZTBVY01zWkFTeUFDM2JpOGJmQkdtcjlGWWxrcFhmbFJid2dIYnZWOXczS0dsNWd4U1JDY1B3bVdsV1Y1TFVWYmVFLUJaSmdQRnNCNkIyaFhSTXE5ZURzM3VlWlA2N2N2WnhudFY2dW9wejJmc2s0R0pzOV9hSHMxX0hZTlc0cEloc2h2a0x2aFNMNWxwcWRZZE9IY04tRUhmQVhPcUtBRlh1MWNqSko0RzB0QklsV3RBMjhoeklYOXFCODZzUjVmVGhtOU93TC1Gb016OW1HOHluUXBJdnhCUXVySGc2ck4yckFhVTM4X3g5?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE81MVlTN25KbEZydEQxV2poX1VXYzk2OExHU0tJYlE4N0M4aEd0cm93ek04WFVRV3pJWjZiZ1FrcExQbWt6emtEUDcwZ1FKdHpRcUJR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:45:30+00:00", "published_display": "24 Apr 2025 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered", "summary": "Kuva Acquisition Corp. has extended its tender offer for Lisata Therapeutics (LSTA) shares to July 16, 2026, with the offer price remaining at $4.00 cash per share plus one contingent value right (CVR) for potential additional payments up to $3.00. Over 5.1 million shares, repres", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-to-t-a-lisata-therapeutics-inc-amended-third-party-tender-offer-adef75046189.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:13", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lisata Therapeutics, Inc. \u2013 NASDAQ:LSTA", "summary": "This article provides the \"Price to sales forward\" value for Lisata Therapeutics, Inc. (NASDAQ: LSTA). It presents the company's stock information, including its ticker symbol, exchange, and market status. Although the specific financial value is not displayed, the article focuse", "url": "https://www.tradingview.com/symbols/NASDAQ-LSTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T16:41:33", "published_display": "08 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline - EPS Growth Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQNnNKbFRGM1dxSWFQMnB6SFJXdVdwejVNYXZveGNETVRpUUxMTUpxcUxZY3F1dllQajV1ZTVQNENZdVJEMHBXazNEQkhERXViVWh3RzVTYV9hcW5NdVhCZElxTlFWUE8zT0ZWcXJkcU5DYU94YTQ5VWdKa0VrVDRNV3hYSkZCRFVzX0RRNFd2Vzhya1NlOC01S2VpWGdXQUYwM3lZeGpwRU5ldnRkcjJJSmQ0QzItOWhpNWJoQ0g1Mk0wUFdoZVZZM1VjSmNlZWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T17:48:31+00:00", "published_display": "07 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) amends 14D-9, restates $4.00 cash offer plus CVR", "summary": "Lisata Therapeutics has amended its Schedule 14D-9 filing to provide additional disclosures regarding the proposed tender offer by Kuva Acquisition Corp. The amendment clarifies board deliberations, an alternative offer, fairness analyses, and includes details about six demand le", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-14d9-a-lisata-therapeutics-inc-amended-tender-offer-recommendation-bff20fb233f8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:27", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA - Lisata Therapeutics Inc Website Traffic and Mobile Apps Usage", "summary": "This article provides a detailed financial and news overview of Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It includes stock performance data, key financial metrics, insider and institutional ownership, and a comprehensive list of corporate news rele", "url": "https://finviz.com/stock?t=LSTA&p=d&ty=tr", "source_name": "Finviz", "published_at": "2026-07-02T10:10:27", "published_display": "02 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE)", "summary": "This article provides current financial actuals and estimates for Lisata Therapeutics, Inc. (DUS:8NE), including income statement, balance sheet, and cash flow data. It also covers stock performance details like all-time high/lows, upcoming earnings dates, net income, EBITDA, and", "url": "https://www.tradingview.com/symbols/DUS-8NE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T23:39:18", "published_display": "26 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides financial information and forecasts for Lisata Therapeutics, Inc. (LSTA), including its stock ticker, historical prices, earnings reports, net income, EBITDA, and employee count. It also addresses frequently asked questions about buying LSTA shares and confi", "url": "https://www.tradingview.com/symbols/BOATS-LSTA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:11:38", "published_display": "26 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing", "summary": "Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (LSTA) on behalf of investors who suffered losses due to disclosures regarding the financing of its proposed acquisition by Kuva Labs, Inc. The investigation follows multiple amendments and delays in the tender offer", "url": "https://www.globenewswire.com/news-release/2026/06/26/3318335/0/en/johnson-fistel-investigates-lisata-therapeutics-inc-lsta-after-disclosures-concerning-acquisition-financing.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T15:11:38", "published_display": "26 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA)", "summary": "This article provides an overview of Lisata Therapeutics, Inc. (NASDAQ: LSTA), covering its current stock price, historical performance, market capitalization, and financial estimates. It highlights key financial data like net income and EBITDA, upcoming earnings dates, and addre", "url": "https://www.tradingview.com/symbols/NASDAQ-LSTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:38", "published_display": "26 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lisata Therapeutics Inc (LSTA), highlighting its price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. As of June 24, 2026, LSTA has a price momentum score of 7.10, wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/technical", "source_name": "TradingKey", "published_at": "2026-06-25T00:09:48", "published_display": "25 Jun 2026 00:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA: Kuva Tender Offer Uncertainty Will Ultimately Support Future Upside Potential", "summary": "Analyst price targets for Lisata Therapeutics have been reduced to $4.00, reflecting increased uncertainty surrounding the proposed Kuva Labs acquisition. Under the tender offer, Lisata shareholders are offered $4.00 cash per share plus a contingent value right (CVR) that could p", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-lsta/lisata-therapeutics/5j4aci8v-positive-clinical-trials-will-expand-precision-oncology-markets-wgss/updates/13-analysts-have-reduced-their-price-target-for-lisata-therapeu", "source_name": "Simply Wall Street", "published_at": "2026-06-23T12:10:45", "published_display": "23 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Institutional Confidence", "summary": "Lisata Therapeutics Inc (LSTA) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 34.03% quarter-over-quarter to 10.92%. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:04", "published_display": "22 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lisata Therapeutics Inc (LSTA) has an earnings forecast score of 7.33, ranking 295 out of 388 in its industry. Analysts have set an average price target of $15.00 for LSTA, with a high of $15.00 and a low of $9.00, and predominantly recommend a \"Buy\" rating for the stock. This an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:09", "published_display": "17 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Lisata Therapeutics Inc (LSTA), including its business segments, regional revenue, and profit contribution. It notes that relevant financial data for these categories have not yet been disclosed by the company. The page provides a ge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Inc (LSTA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lisata Therapeutics Inc (LSTA) stock, focusing on its dividend history and stock splits. It notes that the company has distributed no dividends over the past five years and details a 15-to-1 merger-related stock split that occurred on Septembe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lsta/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)", "summary": "Brodsky & Smith is investigating potential claims against Lisata Therapeutics, Inc. (LSTA) regarding its sale to Kuva Labs, Inc. for $4.00 per share cash plus two contingent value rights. The investigation focuses on whether Lisata's Board of Directors breached fiduciary duties b", "url": "https://www.newsfilecorp.com/release/301602/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Lisata-Therapeutics-Inc.-LSTA", "source_name": "TMX Newsfile", "published_at": "2026-06-15T21:09:50", "published_display": "15 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.", "summary": "Lisata Therapeutics has announced the commencement of a cash tender offer by Kuva Labs Inc., facilitated through its wholly-owned subsidiary, Kuva Merger Sub Inc. This offer is for all outstanding shares of Lisata's common stock at an acquisition price of $0.90 per share. The ten", "url": "https://www.moomoo.com/news/post/71331193/press-release-lisata-therapeutics-announces-commencement-of-tender-offer-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-11T08:39:38", "published_display": "11 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share", "summary": "Lisata Therapeutics has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right up to an additional $3.00 per share tied to drug development milestones. The tender offer launched on June 10, with the offer period set to expir", "url": "https://www.proactiveinvestors.ca/companies/news/1093720/lisata-therapeutics-agrees-to-kuva-labs-buyout-at-4-per-share-1093720.html?region=ca", "source_name": "Proactive financial news", "published_at": "2026-06-11T07:40:02", "published_display": "11 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.", "summary": "Lisata Therapeutics announced that Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., has commenced a tender offer to acquire all outstanding shares of Lisata common stock. Stockholders will receive $4.00 per share in cash plus one non-tradeable contingent value right (CVR) ", "url": "https://www.globenewswire.com/news-release/2026/06/10/3309632/0/en/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-inc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T18:09:51", "published_display": "10 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SC TO-T] LISATA THERAPEUTICS, INC. Third-Party Tender Offer | LSTA SEC Filing - Form SC TO-T", "summary": "This SEC filing (Form SC TO-T) details a third-party tender offer by Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., to purchase all outstanding common shares of Lisata Therapeutics, Inc. for $4.00 per share in cash plus one contingent value right (CVR) that could yield a", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-to-t-lisata-therapeutics-inc-third-party-tender-offer-79b13409144c.html", "source_name": "Stock Titan", "published_at": "2026-06-10T11:39:36", "published_display": "10 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SC 14D9] LISATA THERAPEUTICS, INC. Tender Offer Recommendation", "summary": "Lisata Therapeutics, Inc. (LSTA) has filed an SC 14D9 recommending shareholders accept a tender offer from Kuva Acquisition Corp., a wholly-owned subsidiary of Kuva Labs Inc. The offer comprises $4.00 per common share in cash upfront, plus one non-tradeable contingent value right", "url": "https://www.stocktitan.net/sec-filings/LSTA/sc-14d9-lisata-therapeutics-inc-tender-offer-recommendation-654536a584c9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T08:39:36", "published_display": "10 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQWk52cDdkWURDbWNJa1Y3bUFTTHNuSDc5SXRDYXBnUmJrUXBNWExlazh2Q2pOQWFfN0FMQUJWc0hmUXBoTUJkeUlEYlNXZEg3OE1qR3VzUDZlZzNtSkdnckxsTS1PQUxJLWpaS2E5U2xnRHdSdkFjdHVqaFhfMG5ta0JneW1nN3BkUW5wbzE5TlZSRWhwdGhocnhHV1VkaURvZGxmTDUwRmE0aHZVcFotMU5aelBsM0FXbWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA SEC Filings - Lisata Therapeutics Inc 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides a comprehensive resource for investors to access official regulatory documents for Lisata Therapeutics (LSTA), including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Recent filings detail events such as a non-exclusive AD", "url": "https://www.stocktitan.net/sec-filings/LSTA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T04:39:37", "published_display": "10 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee", "summary": "Lisata Therapeutics and Kuva Labs have amended their merger agreement, extending the tender offer commencement deadline to June 10, 2026, and the transaction \"Outside Date\" to July 17, 2026, with an option for further extension to August 17, 2026, for a $1.5 million fee. Lisata a", "url": "https://www.stocktitan.net/sec-filings/LSTA/8-k-lisata-therapeutics-inc-reports-material-event-4f16e3c4dccb.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:17", "published_display": "09 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17", "summary": "Lisata Therapeutics has extended its merger agreement with Kuva Labs by signing an Amendment and Waiver. This adjustment moves the \"Outside Date\" to July 17, 2026, with a further option to extend to August 17, 2026, for a $1.5 million payment, aiming to navigate financing uncerta", "url": "https://www.tradingview.com/news/tradingview:7ffa76673cfb0:0-lisata-extends-kuva-labs-merger-timeline-outside-date-to-july-17-1-5-million-option-to-aug-17/", "source_name": "TradingView", "published_at": "2026-06-09T11:10:17", "published_display": "09 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSTA - Lisata Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Lisata Therapeutics Inc (LSTA), a clinical-stage pharmaceutical company. It lists key financial metrics, stock performance indicators, and recent news headlines including acquisition efforts by Kuva Labs and vari", "url": "https://finviz.com/stock?t=LSTA", "source_name": "Finviz", "published_at": "2026-06-08T05:11:22", "published_display": "08 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPeTlSVVRnTTRRNG40ZW5KVDFxR2ZFRTFqWFNqSENCa0dVeFpkR2FJLVNfcTV2MzdodXRaOXI2cnhJZEdwZ21vSGExeXo2OGdmRHVVVXRSdHNwc2E1YVNaNGFfbG5Jc1lhaUxkRlZkckZGcTctYjUwcHczeDlTNEdYcmVRaFlFSzVraEQ0anAxcTJMM1daLVVMLWdUeFFMYkt0SzRXSjRobVRIREdSNUVBTldR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNVjVPaWdpOFJGQmJwMHFNSGU3aGZJenp3bmF2NUMwX1FrU1hidGxEbjVFSkI3SlBSSTU1cldNbnBuTDE3YUx4MFZEQWhfaHpsS3BLWUxEQzZiZU9uZEstdjVUTXBHcGk2VWoyRTY3YkFvX2JfUGtDUERIcXR5dVVscVlUVFZ6VTFMaEExck8weHNkb0xuYmNlX0ttNUVIUEpLMTdxd2JBVXlNUEZ0MElPMDdzM1A3Ulp1X2RucWtpdWs4b1c4MmFSc1NITDdqWEk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Slightly Lower: Assessing Support Levels and Potential Catalysts - Sign of Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbGIxX2xQMmtjRjhzLThaakNYUTI4bXpNbGtZOEdscjByZkhOWXVDRkU1Q3loVWllOGpIVTdkUkpTSkhia3pfeXozRVROaWJfdm5yMzhTY2NjVkU4WWVycWNxQkUyamkyMU55WGxXcHZWNC03N3ltWUZ4TUZnZ2FXNS1xdFh1ZE1jX2tXbVZiZmZ2QkFZNkpiV2UxT21JcDIxc09CaGpaQlU0OHZlTjNYOG0wa09zdTNPZ01XZnBmT29EczVOSkF2VU94ZnlwQUFTdlVz?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSXpTNC1GaVF1ODBMSGtEdldSZDhhcDQ3LWEwdnkzUVVENWJvR0d4NHZPVzJEUzlqYzY2WmJpNmlVcDBNb0pqUFNsdDNrSHo3UnZwTzN2Z1hMWnlOMXhoa1ZtYzRrd2pvQk0xNW9hOE1KYUtRVmtoMzZHR1ItbHNrN1hibzlNMW1rOV9jekdORXZaZnFNeW9RRENuWWxsLU9MQlEyRFpiV3VfT1RNQzlqU0RR?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPUnYtOHR0cTg0ZWFqQU1HaDVqZmctY2lreXloYVZjR3oxaEpkRTRqNzdwNm5vTWxValZmT2dGNEp1dk1mR0EwaDlLT2R1MXM3aVdEaTZ1bnlqUWFHazFIT0NKSTd1VmEzeEx2Y0I3Sy1URjREMHFDc1R3VGxfdTZ3RTR0UFhKYXVIaXpON3FwSEV6anVfd20zNl84TmJ1amZES29OdUtOUWhTMlUzQjlNMnBB?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-17T03:48:52+00:00", "published_display": "17 Mar 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNSGtWMldYbl9pOXRmNkpfT3dic0tuQ2docE1pZ0Z1Q3dpckNDVVpra2tnOWM4UFpXZ094eWV4NVlLZWE2TXQyVlcyejNZeUY2bkg0Vl9maDNqeHZ5Q2ViS2ZWSVREVGJrc0ZJcV9INTdUVGFpOTFYNWhUSzBXSlI3WlFfWk5EdW5YVHVaZw?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOMF9vdVdTNUlPejRZbnlfcGF4Um5FdnV3d1lsa0dTZ0FEVnItRUk1ZHpnRmRVRXBYSkp6NlRKM2FyRFBkZFZNaUNHYzFLUlQ2cGk0MXJ2Mm1XcW9jS05EOHZES0pPX3VIM0QyOEVyTkRIdW14STN4VzBWWFZzNVptQkpWd0k4QXB2X2RmOVRuWkJ6NFB1UFNjSkk2ejkwRExoY0tNay1DQ09pUjY0S3dJTUxVakg3Nkc3UXlXTndwMGtXSVJiU1o1dmkwNHJxZndKWXFkZkZCdzBwYUt4SGt5dGIxLVE1M094akZFYw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Shares Nearly Double On Buyout Offer: Here Are The Details", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNSXFETkIzWkZGRHVIdUp3MXBXR0pyVkFSa2NzMHRRdm9kN1BaOTNYZUVDVkhHYjBFS0NQSUdRSGlCRVE5cjZjcVF3VWlqY1U3VHZVS1ZGNVZBSjF4UXROZnVETDNMWmhxNW5oT25xaWVSZ2labXVWQWU2dEpGMHJjVlNSaGNXZkxhSEFRUmtwOTd1aWhxQmZZWkMzb1VhRm5ZcmNwN1I4aXB4bUk?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOam1ERFVaMS1JemRLU290VUxla1Z5VnprNTBTbWE4QnBjYWhGQ0dKU0JnZFBSWERRa3E4UlJtT2g2S25nUUNGWHZ0eEx3d0EyMTJLOXJKZXN2ZUNMcThJS0wyRVR6aGJ5TTF6OHhrU3h2LU9vcktENkJnSUF3dTdtamxKQV95QTN3VmN4OTRFY2tsRHI0c3JvN2RQWXVtR3dqc0ZfVjIxalY?oc=5", "source_name": "citybiz", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics Enters Into Term Sheet to be Acquired", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxOSW0tSmtJUE1wNW5rY2JnbWFBT2NhRXdpVElKbkkwYTEtZlRrbFdtZTBVY01zWkFTeUFDM2JpOGJmQkdtcjlGWWxrcFhmbFJid2dIYnZWOXczS0dsNWd4U1JDY1B3bVdsV1Y1TFVWYmVFLUJaSmdQRnNCNkIyaFhSTXE5ZURzM3VlWlA2N2N2WnhudFY2dW9wejJmc2s0R0pzOV9hSHMxX0hZTlc0cEloc2h2a0x2aFNMNWxwcWRZZE9IY04tRUhmQVhPcUtBRlh1MWNqSko0RzB0QklsV3RBMjhoeklYOXFCODZzUjVmVGhtOU93TC1Gb016OW1HOHluUXBJdnhCUXVySGc2ck4yckFhVTM4X3g5?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lisata Therapeutics (LSTA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE81MVlTN25KbEZydEQxV2poX1VXYzk2OExHU0tJYlE4N0M4aEd0cm93ek04WFVRV3pJWjZiZ1FrcExQbWt6emtEUDcwZ1FKdHpRcUJR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:45:30+00:00", "published_display": "24 Apr 2025 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 45, "sentiment_summary": {"positive": 7, "negative": 7, "neutral": 31, "score": 51, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 8.25, "count": 15}, {"event": "general", "label": "Market update", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 3.27, "latest_week": "2026-07-10", "one_week_move": -1.8, "four_week_move": -8.1, "twelve_week_move": 1.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.831014, "market_dynamics_buy_signal": false, "relative_strength": -8.934047, "fair_value_gap": 13.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.251, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.8% over one week, -8.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "Finviz", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "dars.gov.et", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 15}, {"label": "Market update", "count": 13}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.8% over one week, -8.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lisata Therapeutics (LSTA) holders see Kuva offer extended as over 5.1M shares tendered"}], "updated_at": "2026-07-16T05:13:45.774336+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}